Scientists test Triple-Threat immunotherapy to boost standard lymphoma treatment
NCT ID NCT05455697
Summary
This study is testing whether adding three new immunotherapy drugs (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy is safe and effective for people newly diagnosed with aggressive B-cell lymphomas. The trial will enroll about 35 adults to see if this combination helps the immune system better target and kill cancer cells. Researchers will monitor patients closely for side effects and track how well the cancer responds to treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.